Annals of Nuclear Medicine

Papers
(The H4-Index of Annals of Nuclear Medicine is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Assessing dedicated breast PET performance in breast cancer screening alongside digital mammography, digital breast tomosynthesis, and ultrasound: a reader's insight48
Clinical perspective on targeted alpha therapy using 225Ac44
Comment on “Subcutaneous/cutaneous uptake in the cancer-affected breast on 18F-FDG PET/CT: association with post-surgical prognosis in breast cancer”39
Correction: Novel indices representing heterogeneous distributions of myocardial perfusion imaging31
A first-in-man study of [18F] FEDAC: a novel PET tracer for the 18-kDa translocator protein30
Utility of serum blood ketone levels and other risk factors for inadequate myocardial glucose suppression ketogenic FDG-PET/CT: a prospective and retrospective cohort study27
Adenosine FDG PET/CT reveals potentially viable myocardium in ischemic cardiomyopathy26
Integrating functional and volumetric assessments in 90Y radioembolization: added value of [⁹⁹ᵐTc]Mebrofenin scintigraphy24
18F-FET PET/CT can aid in diagnosing patients with indeterminate MRI findings for brain tumors: a prospective study24
A first-in-man PET study of 2-amino-[3-11C] isobutyric acid for the amino acid transport System A: biodistribution and dosimetry in healthy volunteers21
Vision-language model performance on the Japanese Nuclear Medicine Board Examination: high accuracy in text but challenges with image interpretation19
Research trends and hotspots of radioiodine-refractory thyroid cancer treatment in the twenty-first century: a bibliometric analysis19
Semiquantitative analysis using whole-body dynamic F-18 fluoro-2-deoxy-glucose–positron emission tomography to differentiate between benign and malignant lesions19
FAPI radiopharmaceuticals in nuclear oncology and theranostics of solid tumours: are we nearer to surrounding the hallmarks of cancer?17
Correction: Locoregional indicators of systemic spread in breast cancer: insights from standard-of-care imaging and ¹⁸F-FDG PET/CT17
Comparison of automated bone scan indexes in patients with prostate cancer: aBSI and BONENAVI17
Highly specific amyloid and tau PET ligands for ATN classification in suspected Alzheimer’s disease patients16
Non-metastatic castration-resistant prostate cancer in the epoch of PSMA-ligand PET/CT: twilight?16
0.052324056625366